Supriya Lifescience receives WHO GMP Certification for Ambernath Facility
Approval enables commercial production of formulations with projected revenue potential of ₹500 crore
Author
AI compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging AI across nearly every aspect…
Understanding real-world microbiological outcomes will guide long-term CFTR modulator use in CF:…
Real-world microbiological data reveal complex trends in CFTR modulator therapy, highlighting the need for tailored long-term…
Driving India’s innovation edge
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma…
Panel Discussion: Moving up the value chain without losing volume advantage
India has earned global recognition for making affordable medicines available at scale. But the big question now is: can India…
Next-gen CDMOs: What will they look like
Dr Huzaifa S Choonia, Director & Head, Drug Substance-MSAT, OneSource, spoke on how next generation contract development and…
Secure your Pharma QC-reference standards
The Bengaluru Pharma Event 2025 also featured a detailed session by Dr Markus Obkircher, Director, Head of Customer Solutions…
The R&D playbook for complex generics
Dr Rakesh Bhasin, Head R&D (Formulations), Biocon, gave a presentation on 'The R&D playbook for complex generics'. He…
Panel Discussion: Bengaluru: An emerging global innovation gateway?
Bengaluru, known globally as India’s IT capital, is now fast emerging as a powerful hub for pharma and life sciences. With its…
Challenges in assembly of delivery devices
Bengaluru Pharma Summit 2025 had some really informative sessions that offered actionable insights critical for the pharma…